---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-089270"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2026-08-13T21:25:45+00:00"
generated_at: "2026-08-13T21:28:05.223882+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adial to replace CEO and CFO pending stockholder approval; annual meeting set for Sept 17

## Summary
- CEO Cary Claiborne and CFO Vinay Shah to be terminated effective after 2026 annual meeting if stockholder proposals approved.
- Matthew Davidson, current Chief Development Officer and board member, to become President and CEO.
- New CFO to be appointed; severance payments per amended employment agreements upon release execution.
- Board composition and size changes anticipated, including resignation of legacy board members.
- 2026 annual meeting set for Sept 17, 2026; stockholder proposal deadline Aug 23, 2026.

## SEC filing metadata
- accession: 0001213900-26-089270
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2026-08-13T21:25:45+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390026089270/0001213900-26-089270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390026089270/ea0301965-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-089270
- JSON: https://secwatch.observer/filing/0001213900-26-089270.json
- Plain text: https://secwatch.observer/filing/0001213900-26-089270.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.